Login to Your Account

Clinic Roundup

Monday, October 1, 2012
• MicroDose Therapeutx Inc., of Monmouth Junction, N.J., completed its third and final Phase I study with its inhaled antiviral fusion inhibitor, MDT-637, for the treatment of respiratory syncytial virus. MicroDose presented the data from all three studies at the 8th Annual International Respiratory Syncytial Virus Symposium in Santa Fe, N.M.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription